sulpiride has been researched along with Parkinson Disease in 34 studies
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levosulpiride is a substituted benzamide that is widely used for the management of dyspepsia and emesis." | 5.35 | Levosulpiride-induced movement disorders. ( Chung, SJ; Kim, JS; Kim, MJ; Lee, MC; Shin, HW, 2009) |
| "Levosulpiride is a substituted benzamide that is widely used for the management of dyspepsia and emesis." | 1.35 | Levosulpiride-induced movement disorders. ( Chung, SJ; Kim, JS; Kim, MJ; Lee, MC; Shin, HW, 2009) |
| " Adverse effects were acute dyskinesia (n=2) or parkinsonian syndrome, which occurred after several months or years of treatment (n=15)." | 1.33 | [Extrapyramidal adverse effects of veralipride (Agreal), a drug used to treat hot flushes: a propos of 17 cases]. ( Andréjak, M; Geslin, JM; Gras-Champel, V; Lemaire-Hurtel, AS; Masmoudi, K; Masson, H; Munier, A, 2005) |
| "Levodopa-induced dyskinesias (LID) in Parkinson's disease (PD) may be classified into three main categories: "On" dyskinesias, diphasic dyskinesias (DD), and "off" periods." | 1.28 | Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. ( Gershanik, O; Luquin, MR; Obeso, JA; Scipioni, O; Vaamonde, J, 1992) |
| "The neuroleptic-induced catalepsy was reversed by the classical anti-parkinsonian agent L-DOPA and by agents that function through dopamine systems such as d- and methamphetamine and the direct D2 receptor agonist quinpirole." | 1.28 | Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents. ( Close, SP; Elliott, PJ; Hayes, AG; Marriott, AS; Walsh, DM, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (26.47) | 18.7374 |
| 1990's | 14 (41.18) | 18.2507 |
| 2000's | 7 (20.59) | 29.6817 |
| 2010's | 3 (8.82) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Zarrindast, MR | 1 |
| Fazli-Tabaei, S | 1 |
| Khakpai, F | 1 |
| Cáceres-Chávez, VA | 1 |
| Hernández-Martínez, R | 1 |
| Pérez-Ortega, J | 1 |
| Herrera-Valdez, MA | 1 |
| Aceves, JJ | 1 |
| Galarraga, E | 1 |
| Bargas, J | 1 |
| Naguy, A | 1 |
| AlHumoud, A | 1 |
| Stopper, H | 1 |
| Schupp, N | 1 |
| Fazeli, G | 1 |
| Dietel, B | 1 |
| Queisser, N | 1 |
| Walitza, S | 1 |
| Gerlach, M | 1 |
| Shin, HW | 1 |
| Kim, MJ | 1 |
| Kim, JS | 1 |
| Lee, MC | 1 |
| Chung, SJ | 1 |
| Martí Massó, JF | 1 |
| Ruiz-Martínez, J | 1 |
| Bergareche, A | 1 |
| López de Munain, A | 1 |
| Ohye, C | 1 |
| Shibazaki, T | 1 |
| Kovoor, A | 1 |
| Seyffarth, P | 1 |
| Ebert, J | 1 |
| Barghshoon, S | 1 |
| Chen, CK | 1 |
| Schwarz, S | 1 |
| Axelrod, JD | 1 |
| Cheyette, BN | 1 |
| Simon, MI | 1 |
| Lester, HA | 1 |
| Schwarz, J | 1 |
| Masmoudi, K | 1 |
| Gras-Champel, V | 1 |
| Lemaire-Hurtel, AS | 1 |
| Masson, H | 1 |
| Munier, A | 1 |
| Geslin, JM | 1 |
| Andréjak, M | 1 |
| Brusa, L | 1 |
| Petta, F | 1 |
| Pisani, A | 1 |
| Miano, R | 1 |
| Stanzione, P | 4 |
| Moschella, V | 1 |
| Galati, S | 1 |
| Finazzi Agrò, E | 1 |
| Campbell, DJ | 1 |
| Mendelsohn, FA | 1 |
| Adam, WR | 1 |
| Funder, JW | 1 |
| Pierantozzi, M | 3 |
| Semprini, R | 3 |
| Tagliati, M | 3 |
| Traversa, R | 2 |
| Peppe, A | 2 |
| Pierelli, F | 1 |
| Bernardi, G | 4 |
| Liptrot, J | 1 |
| Holdup, D | 1 |
| Phillipson, O | 1 |
| Strange, PG | 1 |
| Yanagisawa, N | 1 |
| Bodis-Wollner, I | 3 |
| Sarre, S | 1 |
| Ebinger, G | 1 |
| Michotte, Y | 1 |
| Mercuri, NB | 1 |
| Federici, M | 1 |
| Teive, HA | 1 |
| Sa, DS | 1 |
| Lees, AJ | 1 |
| Lander, CM | 1 |
| Stern, GM | 1 |
| Leger, JM | 1 |
| Dumond, JJ | 1 |
| Garoux, R | 1 |
| Lombertie, E | 1 |
| Dumas, M | 1 |
| Graux, P | 1 |
| Durocher, AM | 1 |
| Corsini, GU | 1 |
| Zompo, MD | 1 |
| Cianchetti, C | 1 |
| Mangoni, A | 1 |
| Luquin, MR | 1 |
| Scipioni, O | 1 |
| Vaamonde, J | 1 |
| Gershanik, O | 1 |
| Obeso, JA | 1 |
| Marciani, MG | 1 |
| Lawrence, MS | 1 |
| Redmond, DE | 1 |
| Elliott, PJ | 2 |
| Close, SP | 2 |
| Walsh, DM | 2 |
| Hayes, AG | 2 |
| Marriott, AS | 2 |
| Gershanik, OS | 1 |
| Rubinstein, M | 1 |
| Stefano, F | 1 |
| Joshita, Y | 1 |
| Yamamoto, K | 1 |
| Noda, S | 1 |
| Umezaki, H | 1 |
| Koller, W | 1 |
| Herbster, G | 1 |
| Anderson, D | 1 |
| Wack, R | 1 |
| Gordon, J | 1 |
4 reviews available for sulpiride and Parkinson Disease
| Article | Year |
|---|---|
Is aldosterone secretion under dopaminergic control?
Topics: Aldosterone; Bromocriptine; Chlorpromazine; Dopamine; Dopamine Antagonists; Edema; Humans; Levodopa; | 1981 |
Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
Topics: Basal Ganglia; Basal Ganglia Diseases; Brain; Clozapine; Dopamine Agents; Dopamine D2 Receptor Antag | 1993 |
Electrophysiological assessment of retinal dopaminergic deficiency.
Topics: Animals; Aphakia; Dopamine; Dopamine Antagonists; Electrodiagnosis; Electroretinography; Evoked Pote | 1996 |
[Psychiatric manifestations induced by dopamine precursors or antagonists].
Topics: Anxiety; Bromocriptine; Confusion; Dopamine Antagonists; Dreams; Female; Hallucinations; Humans; Lev | 1979 |
30 other studies available for sulpiride and Parkinson Disease
| Article | Year |
|---|---|
Synergistic effect between quinpirole and L-NAME as well as sulpiride and L-arginine on the modulation of anxiety and memory processes in the 6-OHDA mouse model of Parkinson's disease: An isobologram analysis.
Topics: Adrenergic Agents; Animals; Anxiety; Arginine; Disease Models, Animal; Dopamine Agonists; Dopamine A | 2021 |
Acute dopamine receptor blockade in substantia nigra pars reticulata: a possible model for drug-induced Parkinsonism.
Topics: Action Potentials; Animals; Benzazepines; Disease Models, Animal; Dopamine Antagonists; Dopaminergic | 2018 |
An octogenarian with Parkinson's disease psychosis that has responded favourably to low-dose sulpiride with facilitated motoric agility.
Topics: Aged, 80 and over; Antipsychotic Agents; Humans; Male; Parkinson Disease; Psychotic Disorders; Sulpi | 2019 |
Genotoxicity of the neurotransmitter dopamine in vitro.
Topics: Animals; Antioxidants; Apoptosis; Cells, Cultured; Dopamine; Humans; Micronucleus Tests; Mutagenicit | 2009 |
Levosulpiride-induced movement disorders.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Brain; Female; Humans; Magnetic Resonance Imag | 2009 |
[Parkinsonism induced by sulpiride and veralipride: two different stories].
Topics: Adult; Aged; Brain Damage, Chronic; Contraindications; Dyskinesia, Drug-Induced; Europe; Female; Hum | 2011 |
Lesioning the thalamus for dyskinesia.
Topics: Antiparkinson Agents; Antipsychotic Agents; Dyskinesia, Drug-Induced; Dyskinesias; Electrocoagulatio | 2001 |
D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Antiparkinson Agents; Antipsych | 2005 |
[Extrapyramidal adverse effects of veralipride (Agreal), a drug used to treat hot flushes: a propos of 17 cases].
Topics: Aged; Akathisia, Drug-Induced; Basal Ganglia Diseases; Dopamine Antagonists; Female; Humans; Male; M | 2005 |
Central acute D2 stimulation worsens bladder function in patients with mild Parkinson's disease.
Topics: Domperidone; Dopamine Antagonists; Female; Humans; Male; Middle Aged; Parkinson Disease; Severity of | 2006 |
Increasing doses of l-sulpiride reveal dose- and spatial frequency-dependent effects of D2 selective blockade in the human electroretinogram.
Topics: Adult; Dose-Response Relationship, Drug; Electroretinography; Female; Humans; Male; Parkinson Diseas | 1995 |
1,2,3,4-Tetrahydro-2-methyl-4,6,7-isoquinolinetriol inhibits tyrosine hydroxylase activity in rat striatal synaptosomes.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biopterins; Chromatography, High Pressure Liq | 1994 |
[Diagnosis and treatment of Parkinson's disease in the elderly].
Topics: Aged; Brain; Bromocriptine; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Sulpirid | 1993 |
The visual system in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Contrast Sensitivity; Dopamine; Electroenceph | 1993 |
Levodopa biotransformation in hemi-Parkinson rats: effect of dopamine receptor agonists and antagonists.
Topics: Animals; Antiparkinson Agents; Benzazepines; Biotransformation; Corpus Striatum; Denervation; Dopami | 1996 |
A mixed D1 and D2 antagonist does not replay pattern electroretinogram alterations observed with a selective D2 antagonist in normal humans: relationship with Parkinson's disease pattern electroretinogram alterations.
Topics: Adult; Brain; Electroencephalography; Electroretinography; Haloperidol; Humans; Parkinson Disease; R | 1999 |
Inhibition of catechol-O-methyltransferase (COMT) in the brain does not affect the action of dopamine and levodopa: an in vitro electrophysiological evidence from rat mesencephalic dopamine neurons.
Topics: Animals; Benzophenones; Catechol O-Methyltransferase Inhibitors; Cells, Cultured; Dopamine; Dopamine | 1999 |
Worsening of Parkinsonism after the use of veralipride for treatment of menopause: case report.
Topics: Dopamine Antagonists; Female; Humans; Menopause; Middle Aged; Parkinson Disease; Parkinson Disease, | 2001 |
Tiapride and sulpiride in Parkinson's disease.
Topics: Benzamides; Drug Evaluation; Dyskinesia, Drug-Induced; Humans; Parkinson Disease; Sulpiride | 1978 |
[Value of sulpiride and tiapride in geriatrics. Antagonism between Parkinson disease and chorea].
Topics: Aged; Benzamides; Chorea; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Sulpiride; | 1979 |
Therapeutical efficacy of a combination of apomorphine with sulpiride or metoclopramide in Parkinsonism.
Topics: Adult; Apomorphine; Drug Therapy, Combination; Haloperidol; Humans; Male; Metoclopramide; Parkinson | 1976 |
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.
Topics: Aged; Apomorphine; Chlorpromazine; Dopamine Agents; Dose-Response Relationship, Drug; Dyskinesia, Dr | 1992 |
An electrophysiological study of D2 dopaminergic actions in normal human retina: a tool in Parkinson's disease.
Topics: Adult; Dopamine D2 Receptor Antagonists; Humans; Parkinson Disease; Receptors, Dopamine D2; Referenc | 1992 |
MPTP lesions and dopaminergic drugs alter eye blink rate in African green monkeys.
Topics: Animals; Apomorphine; Blinking; Chlorocebus aethiops; Dopamine Agents; Haloperidol; Male; MPTP Poiso | 1991 |
Neuroleptic-induced catalepsy as a model of Parkinson's disease. I. Effect of dopaminergic agents.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dopamine; Dose-Response Relationsh | 1990 |
Neuroleptic-induced catalepsy as a model of Parkinson's disease. II. Effect of glutamate antagonists.
Topics: Animals; Antipsychotic Agents; Catalepsy; Disease Models, Animal; Dizocilpine Maleate; Fluphenazine; | 1990 |
Inhibitory action of L-dopa.
Topics: Animals; Humans; Levodopa; Mice; Parkinson Disease; Receptors, Dopamine; Receptors, Dopamine D2; Sul | 1989 |
[Studies on the hypothalamic-pituitary dopaminergic system in Parkinson's disease and spinocerebellar degeneration. Response to TRH and sulpiride].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Child; Dopamine; Female; Humans; Hypothalamo-Hypo | 1987 |
[Parkinson's disease associated with trihexyphenidyl (THP) induced dysphonia plicae ventricularis].
Topics: Aged; Female; Humans; Movement Disorders; Parkinson Disease; Sulpiride; Tongue Diseases; Trihexyphen | 1988 |
Quinpirole hydrochloride, a potential anti-parkinsonism drug.
Topics: Animals; Benzazepines; Corpus Striatum; Dogs; Dose-Response Relationship, Drug; Ergolines; Grooming; | 1987 |